The gap between the 400,000+ trials registered on ClinicalTrials.gov and the 3–5% of patients who actually participate isn't a data problem — it's an access and comprehension problem. Here's an honest look at the tools that exist to bridge that gap, and where they still fall short.
What it is: The world's largest registry of clinical trials, maintained by the NIH. As of 2026, it contains over 490,000 studies from 221 countries.
What works: Comprehensive. Authoritative. Updated daily. The v2 API (launched 2023) is dramatically faster and more filterable than the old version. Researchers and coordinators love it.
What doesn't work for patients:
Several companies have built commercial services on top of ClinicalTrials.gov data. Most serve patients through healthcare partners.
These platforms primarily serve pharmaceutical companies and research sites — they're B2B tools that connect sponsors with patient pools. Patients interact through disease-specific websites or physician referral systems rather than a direct consumer app.
Limitation: Coverage is selective (they list trials from paying sponsors), language support is minimal, and the offline or low-bandwidth use case is not addressed.
A free NIH-funded service where patients create health profiles and researchers reach out. Genuinely patient-friendly and free, but requires internet and English literacy, and matching is passive (you wait for researchers to contact you).
Organizations like the National MS Society, American Cancer Society, and Alzheimer's Association maintain curated trial directories for their specific conditions. These are excellent resources for common conditions but don't exist for rare diseases or conditions without large advocacy organizations.
Despite the variety of tools available, several critical gaps remain unaddressed:
The majority of clinical trial information is in English. Globally, 85% of patients don't have English as a first language. For someone with a complex condition who speaks primarily Hindi, Swahili, or Arabic, the existing tools are functionally inaccessible. ClinicalTrials.gov has no translation feature. Commercial platforms don't serve these populations.
In many BoP markets — rural India, sub-Saharan Africa, Southeast Asia — internet connectivity is intermittent and mobile data is expensive. A clinical trial finder that requires a live connection isn't usable by the populations who need it most. Yet every major platform is cloud-dependent.
Even in English, eligibility criteria require medical literacy to parse. "ECOG performance status 0–1," "no prior immunotherapy," "adequate bone marrow function as defined by ANC ≥ 1.5 × 10⁹/L" — these are unintelligible to most patients without clinical training. No major tool automatically translates these into plain language.
If a patient does find a relevant trial and wants to understand what they're agreeing to, the consent form is another 18 pages of clinical language. No tool helps patients parse and understand these documents — they're on their own or dependent on an interpreter.
Patients want to know: "Based on what I know about myself, am I likely to qualify?" Current tools show criteria — they don't help you reason through them. An intelligent eligibility pre-screener that maps patient characteristics to trial criteria would dramatically increase the quality of patient-to-trial matching.
The tool that closes these gaps would need to: work offline, translate into BoP languages, convert medical language to plain language, help patients self-assess eligibility, and support consent form comprehension. No current platform does all of this.
The technology exists — on-device translation (Google ML Kit), ClinicalTrials.gov's free public API, rule-based and AI-based simplification — but it hasn't been assembled into a patient-facing tool designed for populations outside the English-speaking West.
Search ClinicalTrials.gov. Get plain-language summaries. Translate to 10 languages on-device — no internet required after first search. Scan consent forms with your camera. Ask whether you might qualify. Free, always.
Learn About HealthBridge →For informational purposes only. Not medical advice.